A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

Trial Profile

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Anal cancer; Biliary cancer; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Gallbladder cancer; Gynaecological cancer; Lung cancer; Mesothelioma; Neuroendocrine tumours; Salivary gland cancer; Small cell lung cancer; Solid tumours; Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-158
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 13 Jun 2017 Planned End Date changed from 1 May 2019 to 28 Aug 2023.
    • 13 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 28 Aug 2023.
    • 06 Jun 2017 Preliminary results (n=47, as of 19 Oct 2016) assessing the antitumor activity of pembrolizumab in patients with previously treated advanced cervical squamous cell cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top